Although dephosphorylation of tyrosine containing proteins is considered a necessary step in the induction of leukemia cell differentiation by hybrid polar compounds (HPC), the crucial actors in this step remain unknown. We present evidence that tyrosine phosphorylation of JAK1 and JAK2 is down-regulated in murine erythroleukemia cells (MELC) within the first 6 h of their exposure to the prototype of the HPC family, hexamethylenebisacetamide (HMBA), with full recovery at 14 h. Further evidence that the JAKs-centered signalling pathway is switched off early by HMBA was provided by the demonstration that STAT5, a downstream member of this pathway, turned out to be completely dephosphorylated at 6 h in HMBA-treated cells. This JAKs dephosphorylation did not occur in HMBAresistant clones, suggesting that JAKs are possible targets of the dephosphorylative process required for leukemia cell commitment to differentiation. These results may have impact on leukemia therapy based on JAKs inhibitors. Leukemia (2000) 14, 2112-2117.
Introduction
The murine erythroleukemia cell is a widely used model to study the rescue of erythroid differentiation of erythroleukemia cells upon their exposure to various types of inducers, most frequently members of the hybrid polar compounds (HPC) family such as dimetilsulfoxide (DMSO) or hexamethylenebisacetamide (HMBA). [1] [2] [3] While evidence has been gathered that these compounds act in Friend murine erythroleukemia cells (MELC) by modifying the surface potential at the plasma membrane level, and hence modulating voltage sensitive signalling proteins, [4] [5] [6] the identification of the downstream signal pathway is still undefined. However, it has been shown that various classes of inducers, including DMSO and HMBA, profoundly alter the MELC profile of phosphotyrosine-containing proteins, with an almost general decrease in the level of these proteins; moreover, inhibition of phosphotyrosine phosphatases by sodium orthovanadate prevents this decrease, as well as erythroid differentiation. 7 The requirement of tyrosine protein dephosphorylation for cell commitment was also supported by the strong differentiating activity exerted on MELC by simple exposure to a general inhibitor of tyrosine kinases, genistein, 8 as well as by the appearance of specific protein tyrosine phosphatase transcripts upon cell treatment with inducers. 9 After the characterization of the tyrosine phosphorylation cascade centered on the activated erythropoietin-receptor (Epo-R), tyrosine kinases of the JAK family were found deeply Epo-R is expressed in MELC and is constitutively activated by interaction with the glycoprotein gp55 codified by the Friend spleen focus forming virus (FVp). This suggested that such interaction, which occurs in the context of the plasma membrane, is the first step in the transforming process of these cells. 11, 12 Successive studies on the interaction of Epo-R with members of the JAK family in MELC and in other types of cells turned out to be rather complicated and often contradictory. However, a recent report by Yamamura et al 13 contributed substantially to clarify this field, demonstrating that Epo and gp55 activate different JAK-dependent pathways in erythroid progenitors. One pathway has been identified in Epo-responsive erythroblastoid cells from anemic mice, and is constituted of Epo/Epo-R/JAK2. The second pathway is typically operating in FVp-infected cells, and involves the sequence gp55/Epo-R/JAK1. Each of these pathways is apparently sufficient to produce the leukemic transformation, but both can be concomitantly activated in transformed cell lines. As to the role of JAKs in the establishment and maintenance of the leukemic phenotype, Meydan et al 14 showed that leukemic cells from patients in relapse of acute lymphoblastic leukemia displayed constitutively activated JAK2, while the specific inhibition of this kinase by tyrphostin AG-490 selectively blocked leukemic cell growth in vitro and in vivo. Unfortunately, these data are difficult to reconcile with in vitro experiments showing that in SKT6 erythroleukemia cells, JAK2 phosphorylation increases in the very early stage of Epo-induced differentiation. 15 Moreover, in Epo-independent MELC, both DMSO and HMBA enhanced JAK2 tyrosine phosphorylation after 12 h of incubation. 16 We approached this topic in MELC by analyzing the timecourse of JAK1 and JAK2 phosphorylation in HMBA-sensitive and resistant MELC clones exposed to the inducer. We present here evidence supporting that the JAKs tyrosine dephosphorylation is part of a complex modulation of these kinases produced by HMBA at times of cell treatment preceding the irreversible commitment.
Materials and methods

Cell culture
Murine erythroleukemia cells (clone 745 A) were cultured in RPMI 1640 medium (Euro-clone, Paignton, UK) supplemented with 5% fetal bovine serum (FBS) (characterized, Hyclone) (standard complete medium) in 75 cm 2 tissue culture flasks (Corning, Acton, MA, USA). The MELC 12-H clone, selected in our laboratory for its insensitivity to the differentiating activity of HMBA and DMSO, 17, 18 was routinely cultured in standard medium supplemented with 5 mM HMBA.
Differentiation induction
Cells were harvested from preparatory cultures at the density of 1-2 × 10 6 cells/ml and were seeded at 10 5 cells/ml in standard medium, to be incubated for the indicated times in the absence or in the presence of the following substances: 5 mM HMBA (which in our standard experiments induced erythroid differentiation in more than 60% of the responsive cell population at 48 h of exposure); the tyrosine phosphatase inhibitor sodium orthovanadate (Na 3 VO 4 ) (1-100 M); the tyrosine kinase inhibitor genistein (10-100 M).
MELC differentiation was checked by the benzidine assay. This assay was performed according to Orkin et al 19 by using 0.2% (w/v) benzidine in 3% acetic acid (v/v) reacting with 1.5% H 2 O 2 (final concentration). Cells containing hemoglobin appear blue-stained as a consequence of the benzidine reaction with the heme group in the presence of H 2 O 2 .
Cell viability was quantified by cell counting in triplicate on a Bü rker chamber after trypan blue staining.
Cytocentrifugation and staining
Aliquots of cells incubated under various conditions were cytocentrifuged and stained with May-Grü nwald-Giemsa. Paradigmatic pictures were selected for presentation.
Cell extracts
After incubation, cells were collected by centrifugation, washed twice with ice-cold phosphate buffered saline (PBS) containing phosphatase inhibitors (NaF 10 mM, Na-pyrophosphate 10 mM, Na-orthovanadate 0.4 mM) and then lysed in ice for 20 min with lysis buffer (Tris-HCl 20 mM pH 7.4, NaCl 150 mM, glycerol 10%, triton X-100 1%, phenylmetansulphonylfluoride (PMSF) 1 mM, aprotinin 0.15 U/ml, leupeptin 10 g/ml, NaF 100 mM, Na-orthovanadate 2 mM). The supernatant was then cleared by centrifugation at 16000 g. The supernatant was either used directly for electrophoresis of the total extract or treated with antibodies for immunoprecipitation.
Immunoprecipitation, electrophoresis and blot
For the immunoprecipitation of JAK1, JAK2, STAT1, STAT3 and STAT5, 1-5 mg of total cell lysate was incubated overnight at 4°C with polyclonal antibodies: anti-JAK2 (Upstate Biotechnology, UBI, Lake Placid, NY, USA), anti-JAK1 (UBI), anti-STAT1,3,5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Protein-A-sepharose beads were added for 2 h at 4°C and then washed three times with ice-cold PBS. Proteins bound to beads were eluted by boiling the samples in Laemli buffer, 20 analyzed by 7.6% SDS-PAGE under reducing conditions and transferred to a nitrocellulose sheet. The membrane was blocked for 3-5 h at room temperature with PBS + Tween-20 (0.1%) (T-PBS), containing 5% bovine serum albumin (BSA) and then incubated overnight at 4°C with one of the following primary antibodies: anti-phosphotyrosine 4G10 (UBI, 4 g/ml), anti-JAK2 (1:1000 dilution), anti-JAK1 (1:500 dilution), anti-STAT1 (0.5 g/ml), anti-STAT3 (0.5 g/ml), anti-STAT5 (0.5 g/ml). Then, the membrane was washed three times with T-PBS and incubated with anti-rabbit peroxidase-conjugated secondary antibodies (Sigma, St Louis, Leukemia MO, USA) for 1 h at room temperature. After three washes of the nitrocellulose with T-PBS, the immunoreactivity was determined by a chemiluminescent reaction (ECL, Amersham, Arlington Heights, IL, USA). When reprobing of the membrane was necessary, the nitrocellulose sheet was stripped by incubation at 50°C for 30 min in stripping buffer (Tris-HCl 62.5 mM, 2-␤-mercaptoethanol 100 mM, SDS 2%) and then tested for its negativity by ECL.
Results and discussion
Since our MELC clone is Friend-virus transformed, we first checked for the expression and behavior of JAK1, ie the JAK constitutively activated upon cell transformation by this virus. 13 In Figure 1 the time-course of the tyrosine phosphorylation profile (top) and of the total immunoprecipitable protein (bottom) is shown, measured for JAK1 in MELC incubated for different times either in the absence or in the presence of 5 mM HMBA. As expected, JAK1 is expressed and is constitutively tyrosine phosphorylated in the control, increasing its phosphorylation within 14 h. The phosphorylation of JAK1 was reduced in HMBA-treated cells at 6 h of incubation but here also recovered at 14 h. No change in the protein content was observed either in the control or treated cells throughout the experiment.
We then checked for the expression and behavior of JAK2, which has been detected in our and other Friend virus-transformed cell lines. 13, 21, 22 In Figure 2 (top) the time course of JAK2 tyrosine phosphorylation in the absence or the presence of 5 mM HMBA is illustrated. In control cells, the level of tyrosine phosphorylation of JAK2 underwent a certain increase, which was detected 4 h after cell seeding.
HMBA treatment (Figure 2 , top) produced an immediate and progressive decrease in JAK2 tyrosine phosphorylation, with an almost complete disappearance of the corresponding band between 4 and 8 h. At 14 h a strong recovery was observed, attaining levels higher than those of the control. These values were maintained at least up to 20 h (not shown). In the lower part of Figure 2 is shown the immunoprecipitation profile obtained by reprobing the membrane with anti-JAK2 antibodies (␣-JAK2). It is evident that no substantial modulation of the immunoprecipitable protein occurred in the control throughout the experiment; on the other hand, in HMBA-treated cells the immunoprecipitable JAK2 increased after the fourth hour of incubation, at the same time as the decrease in the protein phosphorylation. This behavior is in keeping with the reported increase in the JAK2 mRNA and protein expression which follows the inhibition of JAK2 tyrosine phosphorylation produced by staurosporine in MELC, 21 and suggests the existence of a regulation of JAK2 synthesis linked to the level of tyrosine phosphorylation of this protein.
Taken together, data in Figures 1 and 2 suggest that MELC treatment with HMBA produces a biphasic modulation of JAK1 and JAK2 phosphorylation, consisting of down-regulation followed by complete recovery. This biphasic kinetics may be one major reason for the discrepancy of data reported in the literature, dealing with different experimental models.
The early down-modulation operated by HMBA on JAK1 and JAK2 propagates downstream. In fact, as shown in Figure 3 , HMBA caused a complete dephosphorylation of STAT5, a transcriptional activator which becomes tyrosine phosphorylated by the activated JAK1 and/or JAK2.
13 STAT3 (Figure 3 ) and STAT1 (not shown) turned out to be expressed in MELC but totally unphosphorylated in either control or HMBA-treated cells. However, the STAT5 dephosphorylation has probably no impact on the final cell fate, since in normal and neoplastic erythroid progenitors this protein does not enter the nucleus to accomplish its gene activating task, unless upon a direct EPO-R engagement by EPO. 13 Moreover the functional knock out of its gene did not produce any impairment of normal erythropoiesis. 23 A completely different response of JAKs was obtained when HMBA was added to the MELC clone selected for its resistance to the HMBA-inducing activity (12-H clone). 17, 18 In fact, as shown in Figure 4 , both JAK1 and JAK2 were constitutively expressed in 12-H cells, but as opposed to the wild-type cells, did not display any HMBA-inducible down-modulation of their tyrosine phosphorylation.
Thus, JAKs dephosphorylation correlates with MELC sensitivity to HMBA. In this light, our data suggest that these kinases are precocious and relevant targets of the dephosphorylative process required for leukemia cell commitment to differentiation, 7 a requirement confirmed in our model by the following experiments: (1) wild-type MELC treatment with the tyrosine kinase inhibitor genistein (100 M) for 48 h in the absence of the inducer produced a 90% cell commitment, as compared to 60% in the presence of 5 mM HMBA (not shown); (2) wild-type MELC treatment with the tyrosine phosphatase inhibitor sodium orthovanadate for 48 h produced a dose-response inhibition of cell commitment by HMBA (50% inhibition at 10 M) without affecting cell viability (Figure 5a ). The relevance of this experiment was stressed by analyzing the effects of sodium orthovanadate on the JAK2 phosphorylation level as revealed in a total protein extract obtained from wild-type MELC incubated in the absence or in the presence of 5 mM HMBA; the position of JAK2 was identified by reprobing the membrane with anti-JAK2 antibodies (Figure 5b ). It is evident that under conditions wherein HMBA produces the expected reduction of JAK2 phosphorylation at 6 h, sodium orthovanadate reduces the JAK2 dephosphorylation both in the control and HMBA-treated cells without affecting the amount of protein. This result further supports a cause-effect relationship between the decrease of JAKs phosphorylation and cell commitment.
The effects of various treatments on the phenotype of wildtype and resistant MELC were checked on Giemsa-stained cytocentrifuged slides. Pictures reported in Figure 6 refer to wild-type cells. In Figure 6a are shown typical control cells characterized by large size (25- 30 m) with 80% of the cell area occupied by the nucleus, chromatin distributed in small clumps, and several evident nucleoli. The cytoplasm shows a dense basophilic staining close to the plasma membrane and a large juxtanuclear clear zone. This morphology has been attributed to progenitors of the erythropoietic lineage, possibly CFU-E at which MELC are considered to be blocked. 24 In Figure 6b are shown MELC treated for 4 days with 5 mM HMBA. These cells are characterized by a reduction of the size (10-15 m), with chromatin clumped around the nucleus and disappearance of nucleoli. On the whole these cells resemble polychromatophilic erythroblasts. 25 The HMBAinduced differentiation progresses in several cells up to figures resembling orthochromatic erythroblasts (Figure 6b′) . 25 In Figure 6c are shown MELC treated with 5 mM HMBA plus 25 M sodium orthovanadate for 4 days. It is evident that orthovanadate completely abolishes the erythroid differentiation of MELC which maintain the same phenotype as the controls (see Figure 6a ). In Figure 6d are shown MELC treated with 10 M genistein for 5 days in the absence of HMBA. The morphology of these cells resembles that of HMBA-treated cells (polychromatophilic and/or orthochromatic erythroblasts) (see Figure 6b) although some of them demonstrate a bigger size. These last pictures suggest an irregular erythropoiesis oriented towards the megaloblastic profile. 25 A similar experiment was performed on the 12-H resistant clone which displayed substantially the same phenotype as wild-type control cells, despite their continuous culturing in 5 mM HMBA. This phenotype was not affected by sodium orthovanadate or genistein (not shown).
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Figure 5
Effects of sodium orthovanadate (Na 3 VO 4 ) on HMBA induced MELC differentiation and on JAK2 phosphorylation level. (a) Cells were split at 10 5 /ml and incubated for 48 h in complete medium with 5 mM HMBA and Na 3 VO 4 added at concentrations ranging from 0 to 100 M. /ml and incubated for 6 h in the absence (CON) or in the presence of 5 mM HMBA (HMBA), in both conditions plus or minus 100 M Na 3 VO 4 . At the end of incubation, cells were lysed and protein extracted. This extract was resolved on 7.6% SDS-PAGE, transferred to a nitrocellulose sheet and probed with anti-phosphotyrosine 4G10 antibodies (␣-Ptyr). The filters were then stripped and probed with anti-JAK2 antibodies (␣-JAK2).
Conclusions
Our results might have at least the two following relevant implications. First, while treatments producing general phosphotyrosine dephosphorylation are per se capable of producing MELC differentiation, the analysis of resistant cell response to DMSO led Watanabe et al 7 to suggest that the dephosphorylation of only a limited number of phosphotyrosine containing proteins plays a critical role in triggering differentiation. On the whole, our study contributes to include JAK1 and JAK2 in this number, further stressing the prominent role of JAKs in transducing signals from cytokine receptors. 10 Second, our results can at least in part explain the antitumoral effects displayed by the specific JAK2 inhibitor (tyrphostin AG-490) on the lymphoblastic acute leukemia cells in vivo and in vitro.
14 In fact, we have shown here that the down-regulation of JAKs is an early effect of treatments producing the reversal of the malignant phenotype in leukemia cells. It should be said, however, that in our hands the inhibition of JAK2 by tyrphostin AG-490 turned out to be unable to induce MELC differentiation (not shown). We tend to explain this failure by the fact that in our MELC clone the process leading to rescue of the differentiated phenotype requires that both JAK1 and JAK2 are simultaneously downregulated, implying that the constitutive expression and tyrosine phosphorylation of one of the two kinases is sufficient to maintain the malignant phenotype. Under these conditions, only when both these kinases are inhibited, one should expect the cell commitment to take place. An alternative explanation of the fact that the JAK2 inhibition is ineffective on cell commitment could be that this kinase only performs a redundant task with respect to JAK1 in this process. Unfortunately there is no commercially available specific inhibitor of JAK1, so that the only experimental way to abate both JAKs is the use of a general inhibitor of tyrosine kinases like genistein.
The above interpretation of our data needs, however, to be reconciled with the strong recovery of JAKs phosphorylation, which characterizes the second phase of the HMBA modulation. A clue to this task may be derived from the report that JAK2 phosphorylation is a permissive event of cell recruitment into the S phase. 26 Hence, the early dephosphorylation phase might represent a condition required for the MELC cycle prolongation necessary to accomplish a crucial G1 restricted event. 27 On the other hand, the second phase would restore JAKs phosphorylation levels allowing the cell cycle progression necessary for MELC induction. 27 However, experiments with genistein and orthovanadate here suggest that the JAKs dephosphorylation is an obligate event, whereas the successive restoration can be exploited by alternative pathways promoting the G1-S transition.
